COUNTERFEIT AND ILLEGAL MEDICINAL PRODUCTS AS AN EXAMPLE OF DRUGS THAT DO NOT MEET THE BASIC QUAITY REQUIREMENTS

Agnieszka Kalicka; Natalia Tarłowska

doi:10.56782/pps.164

Data publikacji : 2023-10-26

Tom 21 Nr 4 (2023)

COUNTERFEIT AND ILLEGAL MEDICINAL PRODUCTS AS AN EXAMPLE OF DRUGS THAT DO NOT MEET THE BASIC QUAITY REQUIREMENTS

Agnieszka Kalicka

Natalia Tarłowska

DOI: https://doi.org/10.56782/pps.164

Abstrakt

Falsification or counterfeiting of medicinal products is a severe pharmaceutical crime. According to the World Health Organization, about 10% of medicinal products in developing countries are falsified. In the case of medicines sold over the Internet, the figure is as high as 50%, and this phenomenon's scale
is increasing yearly. The illegally sourced preparations are not manufactured in accordance with Good Manufacturing Practice (GMP). Among the most frequently falsified medicinal products are preparations used for erectile dysfunction, weight loss aids, or anabolic-androgenic steroids. The presence
of undeclared active ingredients and impurities, incorrect dosage due to different than declared contents, and the sourcing of over-the-counter medicines from unknown sources can lead to serious side effects that threaten patients' lives and health. In addition, inaccurate or incomplete descriptions of product formulation can additionally cause the risk of drug interactions, which can consequently lead
to serious medical incidents.

The purpose of this paper is to discuss the requirements for medicinal products and to present the problem of the quality of counterfeit and illegal medicinal products. This issue is discussed using phosphodiesterase type 5 inhibitors (applied to the treatment of erectile dysfunction) as an example.

KEYWORDS: falsified medicinal products, quality of medicinal products, PDE-5 inhibitors

Słowa kluczowe:

sfałszowane produkty lecznicze, jakość produktów leczniczych, inhibitory PDE-5

Podobne artykuły

Łukasz Dobrek, English , Prospects in Pharmaceutical Sciences: Tom 20 Nr 4 (2022)
Aneta Emilia Jabłońska, Krzysztof Adam Stępień, FAŁSZOWANIE PRODUKTÓW LECZNICZYCH ORAZ ZAGROŻENIA WYNIKAJĄCE Z ICH STOSOWANIA , Prospects in Pharmaceutical Sciences: Tom 17 Nr 11 (2019)
Mateusz Sobczyk, Daria Żuraw, Paulina Oleksa, Kacper Jasiński, Mikołaj Porzak, Michał Dacka, SGLT2 inhibitors and their possible use in prevention and treatment of neurological diseases , Prospects in Pharmaceutical Sciences: Tom 22 Nr 1 (2024)
Wojciech Kaźmierski, Jakub Jurek, Paulina Lis, Anna Lis, Anna Ziobro, Mateusz Ziomek, Katarzyna Camlet, Kinga Kocur, Sodium-Glucose Cotransporter-2 Inhibitors In Heart Failure , Prospects in Pharmaceutical Sciences: Tom 22 Nr 3 (2024)
Ewa Napiórkowska, Overview of cyclodextrins and medicinal products containing cyclodextrins currently registered in Poland , Prospects in Pharmaceutical Sciences: Tom 21 Nr 3 (2023)
Dibyajyoti Saha, Satish Kumar Sarankar, Critical review on potentials of ethnopharmacological, ethnomedicinal and traditional practices of Madhuca longifolia (J. Koenig Ex L.) J. F. Macbr. (Family: Sapotaceae) , Prospects in Pharmaceutical Sciences: Tom 21 Nr 2 (2023)
Krzysztof Adam Stępień, Jakub Niewiarowski, Anna Harasimiuk, POWSZECHNOŚĆ SUPLEMENTÓW DIETY A ZAGROŻENIA ZWIĄZANE Z ICH STOSOWANIEM , Prospects in Pharmaceutical Sciences: Tom 17 Nr 9 (2019)
Maciej Bara, Jakub Starownik, Jakub Szydło, Patryk Gryszkiewicz, Jakub Nieznański, Dapagliflozin - new solution in chronic kidney disease treatment , Prospects in Pharmaceutical Sciences: Tom 22 Nr 2 (2024)
Barbara Krzemińska, Gabriela Szewczyk, Cotoneaster horizontalis Decne. (Rosaceae) - the medicinal or just ornamental species? , Prospects in Pharmaceutical Sciences: Tom 22 Nr 2 (2024)
Anna Dominiczak, Agata Janczak, Martyna Wołek, Katarzyna Mazurek, Maciej Bara, PROTON PUMP INHIBITORS: PROLONGED INTAKE AND ADVERSE EFFECTS. , Prospects in Pharmaceutical Sciences: Tom 22 Nr 4 (2024)

1 2 3 4 5 6 7 > >>

Możesz również Rozpocznij zaawansowane wyszukiwanie podobieństw dla tego artykułu.

Szczegóły

Bibliografia

Statystyki

Autorzy

Pobierz pliki

PDF (English)

Zasady cytowania

Kalicka, A., & Tarłowska, N. (2023). COUNTERFEIT AND ILLEGAL MEDICINAL PRODUCTS AS AN EXAMPLE OF DRUGS THAT DO NOT MEET THE BASIC QUAITY REQUIREMENTS. Prospects in Pharmaceutical Sciences, 21(4), 10–23. https://doi.org/10.56782/pps.164